Clearside macular edema program headed for submission

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA met the primary endpoint in the Phase III PEACHTREE trial to treat macular edema associated with non-infectious uveitis. Clearside plans to submit

Read the full 307 word article

User Sign In